FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares
Rhea-AI Summary
FocalTherics (NASDAQ: FOCL) has priced an underwritten public offering of 8,425,000 American Depositary Shares (ADSs), each representing one ordinary share with €0.13 nominal value, at a public offering price of $4.75 per ADS, before underwriting discounts and commissions.
All ADSs will be sold by the company, which expects gross proceeds of about $40.0 million, excluding the underwriters’ 30‑day option to buy up to 1,263,750 additional ADSs. The offering, made under an effective Form S‑3 shelf registration, is expected to close on August 14, 2026, subject to customary conditions. TD Cowen and Mizuho are joint book‑running managers, with H.C. Wainwright & Co. and Lucid Capital Markets as co‑managers.
Positive
- Underwritten ADS offering targets ~$40.0 million in gross proceeds
- Upsize option for underwriters of up to 1,263,750 additional ADSs
- All ADSs sold by company, enhancing primary capital rather than selling shareholders
Negative
- New issue of 8,425,000 ADSs implies shareholder dilution at $4.75 per ADS
- Underwriters’ discounts, commissions and offering expenses will reduce net proceeds below $40.0 million
News Explained
If completed, the company—not existing holders—receives about $40.0 million gross while issuing 8,425,000 ADSs, reducing existing percentage ownership.
The FocalTherics announcement puts the offering at the priced stage, with closing still expected on
An underwritten offering means an investment bank buys securities from the issuer for resale, and fees reduce net proceeds below gross proceeds; the Form S-3 shelf authorizes future capacity but does not itself sell shares.
On a dollar basis, the expected
Sources and calculations
- FocalTherics public offering pricing announcement (2026-08-11)
- Dilution definition (undated)
- Underwritten offering definition (undated)
- Form S-3 purpose (undated)
- FocalTherics first-quarter 2026 fundamentals (2026Q1)
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $15,012,000 / ($2,972,000 / 90) = [object Object]
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 30 | Earnings scheduling | Neutral | -0.3% | Company scheduled second-quarter 2026 results and conference call for August 13. |
| Jun 30 | Commercial launch | Positive | +0.7% | Company launched its first European commercial endometriosis Focal One program. |
| Jun 16 | Healthcare agreement | Positive | +0.0% | Agreement expanded Focal One access across VA and Department of Defense systems. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The stock aligned with positive launch news once, while a neutral scheduling notice preceded a negative move and another positive announcement had no price change.
Key Terms
underwritten public offering financial
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares
AUSTIN, Texas and LYON, France, Aug. 11, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (NASDAQ: FOCL) (the “Company”), a global leader in robotic energy-based therapies, announced the pricing of its underwritten public offering of 8,425,000 of American Depositary Shares (“ADSs”), each representing one ordinary share of the Company,
TD Cowen and Mizuho are acting as joint book-running managers for the Offering. H.C. Wainwright & Co. and Lucid Capital Markets are acting as co-managers for the Offering.
The Offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-294597), previously filed with the Securities and Exchange Commission (the “SEC”) on March 25, 2026, amended on March 27, 2026, and declared effective on March 31, 2026. The Offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the proposed Offering will be filed with, and will be available on, the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting: TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by email at TDManualrequest@broadridge.com; Mizuho Securities USA LLC, Attention: Equity Capital Markets, 1271 Avenue of the Americas, 3rd Floor, New York, NY 10020, by telephone (212) 205-7600, or by email: US-ECM@mizuhogroup.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. In particular, no public offering of the ADSs will be made in Europe.
About FocalTherics
A recognized global leader in Robotic Focal Therapy, FocalTherics develops, manufactures, and markets minimally invasive medical devices worldwide to treat various conditions using proprietary focused ultrasound technology. The Company’s flagship platform, Focal One Robotic HIFU, combines advanced imaging, real-time treatment planning, robotic precision, and HIFU technology to deliver personalized focal therapy designed to optimize clinical outcomes while preserving quality of life.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements within the meaning of applicable federal securities laws, including Section 27A of the U.S. Securities Act of 1933 (the “Securities Act”) or Section 21E of the U.S. Securities Exchange Act of 1934, as amended, including statements about the Company’s expectations regarding the Offering, including the expected timing and the Company’s expectation that it will complete the Offering, which may be identified by words such as “believe,” “can,” “contemplate,” “could,” “plan,” “intend,” “is designed to,” “may,” “might,” “potential,” “objective,” “target,” “project,” “predict,” “forecast,” “ambition,” “guideline,” “should,” “will,” “estimate,” “expect” and “anticipate,” or the negative of these and similar expressions, which reflect the Company’s views about future events and financial performance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to the Company or not currently considered material by the Company, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, but are not limited to, uncertainties related to market conditions, those risks relating to the Offering and others described in the preliminary prospectus supplement, final prospectus supplement and in particular in the sections “Cautionary Statement on Forward-Looking Statements” and “Risk Factors” and those risks relating to the Company’s business, which are described in the Company’s filings with the SEC and in particular in the section “Risk Factors” in the Company's Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q.
Forward-looking statements speak only as of the date they are made. Other than required by law, the Company does not undertake any obligation to update them in light of new information or future developments. These forward-looking statements are based upon information, assumptions and estimates available to the Company as of the date of this press release, and while the Company believes such information forms a reasonable basis for such statements, such information may be limited or incomplete.
Investor Contact
Louisa Smith
Gilmartin Group
investor.relations@focalone.com
